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Introduction1
Substitution treatment programmes were 
launched in Finland in 1997 in response to 
the increase of HIV infections in the 1990s, 
related to increasing abuse of opioids and 
other drugs. Since then, the objectives and 
practices of treatment have been under 
continuous change in our country (Selin, 
Hakkarainen, Partanen, Tammi & Tiger-
stedt, 2013). Recent developments, such as 
establishing harm reduction-oriented sub-
stitution treatment as an option to reha-
bilitation, has raised some concern about 
treatment becoming routine-like adminis-
tration of medication without the psycho-
social rehabilitation that constitutes the 
foundation for substance abuse treatment 
(Table 1). In addition, the general pressure 
to improve the cost-efficiency of substance 
abuse services has given rise to concern, 
as this is considered to lead to too limited 
treatment practices (Perälä, Hellman, Lep-
po, 2013). However, knowledge of the ac-
tual developments of opioid substitution 
treatment is still fragmentary. 
The Nordic countries have similar wel-
fare systems, and their substance use cul-
tures are relatively similar in an interna-
tional context. Therefore, comparisons be-
tween Nordic countries may cast light on 
the functioning of the Finnish treatment 
system. In this article, we first briefly dis-
cuss the history of substitution treatment 
and drug abuse treatment policies in the 
Nordic countries. Then we picture the cov-
erage and extent of treatment and different 
patient groups in these countries. Next, 
we describe the objectives and quality of 
treatment in each country, focusing on na-
tional guidelines on treatment practices. 
Finally, we discuss the treatment systems 
from the point of view of discontinuation 
rates and mortality rates during treatment. 
The comparison of treatment systems is 
flexibly based on the conceptual model 
of Babor, Stenius, and Romelsjö (2009) on 
treatment systems. In this model, charac-
teristics of treatment systems (e.g. efficien-
cy, fairness), treatment policies, structural 
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Table 1. Harm reduction and rehabilitation as treatment aims in opioid substitution 
treatment.
The Finnish decree on the treatment of opioid dependent persons (33/2008) defines substitution treatment in 
terms of its aims: “aim is either rehabilitation and abstinence or harm reduction and improvent in the patient´s 
quality of life”. The usage of terms “rehabilitative substitution treatment” and ”harm reduction” in the article 
ascend from this Finnish vocabulary, but they are also used to analyse treatment systems in other Nordic 
countries. This is justifiable, because the terms reflect two major approaches in international drug treatment 
policies: one emphasising abstinence as the ultimate treatment aim and the other improvements in the quality 
of life and the reduction of harms related to drug use.  
resources (e.g., treatment methods) and 
patients’ social and health status are con-
sidered to affect the treatment outcomes. 
Our sources include mainly studies and 
reports on national drug abuse policies in 
Nordic countries; substitution treatment 
regulations and treatment guidelines; sur-
veys and reports on substitution treatment; 
and Nordic and international research lit-
erature relating to substitution treatment. 
In addition, we asked the authorities in 
each country, or the institutes that are 
responsible for nationwide collection of 
data, to provide such information on sub-
stitution treatment that was not available 
from other sources. Thus, the article also 
provides new information. Data was col-
lected in 2014.
Substitution treatment in 
Nordic countries
Today, substitution treatment of opioid de-
pendence is an established part of national 
drug abuse treatment systems in all Nordic 
countries. The number of patients receiv-
ing substitution treatment is significant in 
each country and has been continuously 
increasing lately, with the exception of 
Denmark where developments were ear-
lier (The European Monitoring Centre for 
Drugs and Drug Addiction [EMCDDA], 
2013a). In addition, criticism on substi-
tution treatment has become less intense 
and substitution treatment has become not 
only a part of normal discourse in Nordic 
substance abuse and opioid treatment ser-
vices, but more and more frequently the 
key topic of general discussion on sub-
stance abuse treatment (Skretting & Rosen-
qvist, 2010). 
The expansion and establishment of 
substitution treatment have followed dif-
ferent patterns in each country, which also 
reflects differences in treatment policies 
between the countries. Moreover, there 
are many differences related to treatment 
and treatment practices. Denmark has 
been providing opioid treatment since 
the 1960s, and the treatment practices are 
more customer-driven compared with the 
other Nordic countries (Thom, Duke, Ass-
mussen & Bjarge, 2013; Asmussen, 2006). 
In March 2009, Denmark initiated heroin 
substitution treatment, which can be con-
sidered as a radical move in the Nordic 
context (Sundhedsstyrelsen, 2013a). 
Until recent years, Sweden and Norway 
have considered substitution treatment as 
‘an exception to the rule’, with the basic 
rule being rehabilitation without medica-
tion. Sweden still applies strict rules to 
the implementation of substitution treat-
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ment, and strict criteria to admission to 
treatment with evidence of long-term opi-
ate abuse (Skretting & Rosenqvist, 2010). 
Swedish substitution treatment is like a 
mirror image of the Swedish drug policy, 
which takes a very strict approach to the 
drug problem and is based on the idea of 
total abstinence as the goal of treatment 
(Ekendahl, 2009). Finland and Norway 
both have what has been called a dual 
track policy (Tammi, 2007), with strict 
drug policy but elements of harm reduc-
tion in drug treatment.
The Finnish and Norwegian substitu-
tion treatment policy can be placed in the 
middle ground between Sweden and Den-
mark. Finland initiated substitution treat-
ment in the 1990s, which was relatively 
late. It was met with strong resistance at 
first, and similar to Sweden and Norway, 
the admission criteria were then strict. In 
the 2000s, however, Finland has consider-
ably eased these criteria compared with 
Sweden. Harm reduction in addition to re-
habilitative treatment is now emphasised 
more strongly (Skretting & Rosenqvist, 
2010). 
What is common for all Nordic coun-
tries is the government’s role as the finan-
cier and organiser of the treatment, as well 
as differences in opinions on substitution 
treatment between the social and health 
care sectors. In Finland and the other Nor-
dic countries, the expansion of substitu-
tion treatment has led to critical discus-
sion on the ‘medicalisation’ of treatment 
and the minor role of psycho-social care 
(Thom et al., 2013; Perälä et al., 2013). 
Coverage of substitution 
treatment, number of patients 
and patients’ sociodemographic 
background in Nordic countries 
The reliability of estimates of the number 
of problem opioid users2 (Table 2) varies be-
tween the Nordic countries. For example, 
only an estimate of the number of inject-
ing drug users (13,000) is available from 
Denmark, but no estimate of the number of 
opioid problem users (Sundhedsstyrelsen, 
2013b). For Finland, there is an estimate 
available that is based on data from 2012, 
according to which Finland has 13,000–
15,000 problem opioid users (Ollgren et 
al., 2014). The Swedish Socialstyrelsen 
provides an exact figure (7,237), based on 
recorded opioid dependence diagnoses of 
clients of social and health care services 
and previous estimates on the number of 
abusers (Socialstyrelsen, 2012). The reli-
ability of the Swedish figure may be com-
promised for the reason that many prob-
lem drug users, in fear of stigmatisation, 
do not seek treatment at all or conceal their 
drug abuse when using social and health 
care services (EMCDDA, 2012a). In the 
Nordic countries, the estimated number of 
problem opioid users (particularly users of 
opiates, such as heroin) is thus highest in 
Finland, Denmark, and Norway and low-
est in Sweden and Iceland. What is spe-
cific for Finland is that the most abused 
opioid is buprenorphine (Forsell & Nurmi, 
2013).
The number of patients in substitution 
treatment varies greatly (Table 2). In Den-
mark, the number of patients has fallen 
from 7,850 in the peak year 2010 to 7,600 
patients in 2011 (EMCDDA, 2013a). It 
seems that Denmark is going in a different 
direction than the other Nordic countries, 
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Table 2. Number of opioid substitution treatment patients, problem opioid users, and 
coverage of treatment.
Variable Finland1 Sweden2 Norway3 Denmark4 Iceland5
Number of patients 2,439 5,252 7,038 7,600 90–100
Units 161 114 n.a. 58 1
Problem opioid users* 
(share of pop.)
13,000–15,000
(0,24-0,28 %)
7,237
(0,07 %)
9,450
(0,18%)
13,000
(0,23 %)
200
(0,06 %)
Coverage 16–19% 73% 74% n.a. appr. 50%
* Estimates of the numbers of opioid problem users in different countries are based on varying methodologies.
1 Data for Finland from 2011 (Partanen et al., 2014), except the estimate of problem opioid users, which is from 2012 
(Ollgren, 2014). The coverage estimate is based on the ratio between the estimated number of problem opioid users 
and the number of substitution treatment patients.
2 Data for Sweden from 2012 (Socialstyrelsen, 2012). The estimate of the number of patients is based on the number 
of diagnosed opiate dependence cases entered in the official registers. 
3 Data for Norway from 2012 (Waal et al., 2013), except the estimate of problem opioid users, which is from 2008 (EM-
CDDA 2013c). The coverage estimate is based on the ratio between the estimated number of problem opioid users 
and the number of substitution treatment patients.
4 The data for Denmark from 2011 (number of patients) and 2006 (estimated number of injecting drug users) (Sund-
hedsstyrelsen, 2013b). There is no data on the exact number of opioid abusers, but it is estimated that most injecting 
drug users are opioid users (Sundhedsstyrelsen, 2013b). 
5 Data from 2013 (V. Rúnarsdóttir, personal communication, 7 March, 2014). The number of problem opioid users 
includes both injecting drug users and other abusers of pharmaceutical opioids. 
where the number of patients is on the in-
crease. The probable reason for this is that 
Denmark officially initiated substitution 
treatment as early as the 1960s and ex-
panded it strongly in the 1980s and 1990s 
– that is, at a time when the other Nordic 
countries were still only planning the im-
plementation or controlled expansion of 
substitution treatment (Skretting & Rosen-
qvist, 2010; Houborg, 2012). The rapid in-
crease in the number of patients in Nor-
way is worth mentioning: there were 2,431 
patients in substitution treatment in 2003, 
5,058 in 2007 and as many as 7,038 in 
2012 (EMCDDA, 2013a; Waal, Bussesund, 
Clausen, Håseth, & Lillevold, 2013). Also 
in Sweden there has been a considerable 
increase during the last ten years.
Based on the estimated number of prob-
lem opioid users and the number of pa-
tients in substitution treatment, it is pos-
sible to make rough estimates of the cover-
age of substitution treatment in the Nordic 
countries (Table 2). According to relatively 
recent surveys conducted in Sweden and 
Norway, there are considerable regional 
differences in coverage (Socialstyrelsen, 
2012; Waal et al., 2013). Detailed region-
al figures are not available for Finland 
and Denmark, but in Finland at least it is 
quite possible that there is considerable 
variation in regional coverage (Partanen, 
Vorma, Alho, & Leppo, 2014). In Finland 
the coverage seems to be lower compared 
with the other Nordic countries. It should 
also be noted that the estimate of the num-
ber of problem opioid users in Finland is 
not directly comparable with other Nordic 
countries. 
In prisons, Norway and Denmark offer 
the most extensive substitution treatment 
services. In Norway, the number of prison-
ers receiving treatment has also increased 
rapidly, from 766 patients a year in 2011 to 
922 in 2012 (EMCDDA, 2013c; Helsedirek-
toratet, 2013). In Finland and Sweden, the 
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Table 3. Substitution treatment patients in Nordic countries.
Variable Finland1 Sweden2 Norway3 Denmark4 Iceland
Mean age (yrs) 34 n.a. 42 n.a. n.a.
Women 31% 27% 30% 23% n.a.
Only basic education or less 62% n.a. 62% 51% n.a.
Employed 7% n.a. 15% 7% n.a.
Homeless 4% 0% 3% 3% n.a.
1 Data for Finland from 2012 (Forsell & Niemi, 2013).
2 Data for Sweden from 2012 (Socialstyrelsen, 2012).
3 Data for Norway from 2012 (Waal et al., 2013), except the education data, which was obtained from a follow-up 
study conducted in 1998–2009 (Lauritzen et al., 2012).
4 Data for Denmark on patients who initiated treatment in 2010–2014 (K. Frederiksen, personal communication, 21 
February, 2014). In addition, 20.8% of the patients belonged to category ‘no education or education unknown’. Thus, 
the percentage of those with only basic education is probably higher than the figure in the table indicates.
number of prisoners in treatment is still 
very low (Partanen et al., 2014; EMCDDA, 
2013c). 
The socio-demographic background of 
substitution treatment patients seems to 
be largely similar in all Nordic countries 
(Table 3). The oldest patients are found 
in Norway, where nearly 90% of them 
are at least 31 years of age (Waal et al., 
2013). The proportion of women is low-
est in Denmark, only approximately 23% 
(K. Frederiksen, personal communication, 
21 February, 2014) and highest in Finland, 
31% (Forsell & Nurmi, 2013). Clearly 
over half of the patients in each country 
have completed only basic education or 
less. Employment rates are also very low. 
Norway has the highest employment rate, 
15% (24% in Central Norway) (Waal et al., 
2013). Homelessness is not very common. 
In this context, ‘homeless’ refers to people 
who have been labelled as homeless in 
statistics. It is possible that the number of 
homeless is actually higher, either because 
of missing data or for reasons such as im-
prisonment or institutional care at the time 
of collecting data. In Sweden, the virtually 
zero homelessness rate is explained by the 
fact that you cannot be admitted to sub-
stitution treatment without a permanent 
address (Petersson, 2013). In a Finnish 
12-year follow-up study of clients of drug 
abuse services at the Helsinki Deaconess 
Institute, 27% (n=780) of patients who 
had sought treatment due to buprenor-
phine abuse were homeless (Uosukainen 
et al., 2013). This figure is many times 
higher compared with nation-level data 
on clients of drug abuse services, accord-
ing to which 4% of substitution treatment 
clients were homeless (Forsell & Nurmi, 
2013). It seems that in Finland, the per-
centage of homeless is lower among sub-
stitution treatment patients than among 
other patients who have sought treatment 
for opioid abuse. 
Objectives and quality of 
substitution treatment in Nordic 
countries
According to the decree that entered into 
force in Finland in 2008 (33/2008), substi-
tution treatment may involve detoxifica-
tion aiming for substance-free life; reha-
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Table 4. Objectives and content of substitution treatment in Nordic countries.
Variable Finland
1 Sweden2 Norway3 Denmark4 Iceland5
Treatment aim Rehab./
Harm red.
Rehab. Rehab./
Harm red.
Harm red./
Rehab.
n.a.
Waiting time (wks) max. 12–24 6–8 3–12 2 n.a.
Preconditions
Age limit (yrs) none 20 none none n.a.
Dependency Opioid/opiate Opiate Opioid/opiate Opioid/opiate n.a.
Duration of dependency none 12 months none none n.a.
Commonest reason for 
discontinuing
n.a. Involuntary Voluntary Voluntary n.a.
Medications
methadone 38% 45% 44% 82% 5%
Buprenorphine products 62% 51% 56% 18% 95%
1 Data from 2011 and 2012 (Partanen et al., 2014, Kuljukka et al., 2014).
2 Data from 2012 (Socialstyrelsen, 2012).
3 Data from 2012 (Waal et al., 2013).
4 Data from 2011 (EMCDDA, 2013f).
bilitative substitution treatment aiming 
for rehabilitation and substance-free life; 
or substitution treatment aiming for harm 
reduction and improved quality of life. 
Even though the implementation of sub-
stitution treatment in Finland is regulated 
by a decree and Current Care Guidelines 
on substitution treatment exist, Finland 
does not have national-level handbooks 
specifying the content of treatment in de-
tail as in Norway, Denmark and Sweden 
(Helsedirektoratet, 2010; Sundhedsstyrels-
en, 2008; Socialstyrelsen, 2015). However, 
local or regional guidelines are in place. 
According to the data collected by the 
Kuusikko working group established by 
the six largest local authorities of Finland, 
the costs of substitution treatment in 2012 
totalled EUR 7.8 million (EUR 5,056 per 
patient) (Kuusikko-työryhmä, 2013). Wait-
ing times for substitution treatment have 
become shorter in Finland over the years, 
but there is local variation. Maximum 
waiting times may be 12 to 24 weeks, 
within the limits set by the maximum 
waiting time guarantee applied in basic 
health care and specialised medical ser-
vices (Kuljukka, Niskala, Partanen, Kuus-
saari, & Vorma, 2013). 
In Finland, the use of buprenorphine 
products as medication is more common 
than in the other Nordic countries, at the 
same time as abuse of buprenorphine 
products is the most common reason for 
seeking substitution treatment (Table 4).
In Denmark, the country with the most 
liberal drug policy, substitution treatment 
aims for the reduction of harmful effects 
related to drug use. Local authorities are 
responsible for substitution treatment. Pro-
viders of medically assisted drug treatment 
and non-medical ‘social treatment’ (social-
behandling) work in close co-operation. In 
Denmark, patients are guaranteed access 
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to treatment, and psychosocial treatment 
should be initiated within 14 days of the 
day when the client expressed his or her 
willingness to start drug abuse treatment. 
Substitution treatment is usually initiated 
at the same time. The criteria for admis-
sion to treatment include opioid depend-
ence diagnosis, willingness to treatment 
expressed by the patient and an assess-
ment of the unsuitability of alternative 
forms of treatment. Before treatment with 
buprenorphine products is initiated, the 
patient must have abstained from opioids 
long enough to experience first withdrawal 
symptoms. Upon the initiation of metha-
done, the patient must not be intoxicated. 
Thus, the threshold for initiating treat-
ment is quite low. Methadone is usually 
administrated on a daily basis as oral so-
lution, tablets or intravenous injections. 
Take-home doses are also possible. Pa-
tients inject intravenous methadone them-
selves. This treatment is only for patients 
with long-term abundant intravenous use 
of drugs during the substitution treat-
ment. The treatment of a violent patient 
may be terminated, but in this event, the 
patient must be referred to other services 
that guarantee the continuation of medi-
cal treatment (Sundhedsstyrelsen, 2008). 
Methadone is by far the most common 
medication, and only 1,400 patients (18%) 
are receiving buprenorphine or a combina-
tion product that contains buprenorphine 
and naloxone, although, similar to the oth-
er Nordic countries, Danish guidelines rec-
ommend buprenorphine products as the 
primary medication for substitution treat-
ment. Denmark is different from the other 
Nordic countries in that heroin treatment 
is allowed. From April 2009 to Decem-
ber 2012, 252 people had received heroin 
treatment (Sundhedsstyrelsen, 2013b).
In Norway, substitution treatment has 
two goals: improving patients’ quality of 
life and supporting their functional abil-
ity, while reducing harmful effects and the 
risk of dying from an overdose (Forskrift 
om legemiddelassistert, 2009). Patients’ 
own wishes are the basis for the determi-
nation of treatment objectives (Helsedi-
rektoratet, 2010). The choice of treatment 
must always be preceded by assessment 
of the suitability of other treatments. In 
particular, the patient’s age and the du-
ration (according to ICD-10/DSM-IV) of 
opioid dependence must be taken into 
account when assessing the suitability 
of opioid treatment. Guaranteed access 
to treatment ensures that an assessment 
of the need for treatment is conducted 
within 30 week days (within 10 days for 
patients less than 23 years of age). After 
the assessment, a deadline is set by which 
the patient’s treatment must begin. The 
deadline is based on the severity of the pa-
tient’s situation. The waiting time varies 
from a couple of weeks to a few months. 
Patients are admitted to treatment rela-
tively quickly (within three to 12 weeks) 
(Waal et al., 2013). Before the initiation 
of treatment, the patient must stop taking 
alcohol, benzodiazepines and hypnotics 
(Forskrift om legemiddelassistert, 2009). If 
the treatment is initiated with a buprenor-
phine product, at least eight hours must 
have passed since the patient’s previous 
opioid dose and the patient must be expe-
riencing mild withdrawal symptoms. At 
the beginning of treatment, the medica-
tion must be taken under supervision. For 
three months, the patient must come every 
day to pick up the daily dose. Take-home 
doses may be given for a week at the most. 
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For the first three months of treatment, 
drug screens are performed twice a week 
and then at least twice a year. Involuntary 
discontinuation of treatment is possible 
only in the event that the patient does not 
comply with safe treatment despite vari-
ous control and support measures. Other 
treatment is offered to such patients. Treat-
ment may be discontinued if the patient is 
violent or threatens with violence and is 
incapable of better self-control despite re-
peated attempts (Helsedirektoratet, 2010). 
The costs of substitution treatment in Nor-
way in 2010 were estimated at EUR 10,855 
(NOK 90,500) per patient per year (Waal, 
Clausen, Håseth, & Lillevold, 2011).
In Sweden, successful rehabilitation is 
the objective of treatment. According to 
the decree that came into effect in 2010, 
the preconditions for initiation of treat-
ment are 20 years of age and a demonstrat-
ed history of at least 12 months of opiate 
dependence, that is, dependence of opium 
alkaloids and their derivatives obtained 
from the opium poppy, such as heroin, 
morphine or codeine. Users of syntheti-
cally produced opioids (such as buprenor-
phine) are not admitted to treatment. The 
age limit (20 years) can be disregarded for 
a weighty reason. In Sweden, patients are 
admitted to treatment within six to eight 
weeks on average. Treatment is initiated 
on the basis of a psychiatrist’s examination 
conducted at a treatment unit that pro-
vides substitution treatment. Treatment 
cannot be initiated if the patient is addict-
ed to alcohol or other substances that in-
volve a medical risk. Patients whose sub-
stitution treatment was discontinued less 
than three months ago cannot be admitted 
to treatment. In addition, patients who are 
in involuntary treatment under the Act 
on the Treatment of Alcoholics and Drug 
Misusers are not admitted. Prior to initiat-
ing treatment, a treatment plan is drafted 
in co-operation with the patient. At least 
for the first two months of treatment, the 
patient must each day take the medication 
under supervision at a specified location. 
Then the patient may be given take-home 
doses if the doctor decides that this is suit-
able (Läkemedelsassisterad behandling, 
2009). For the first six months, the patient 
must give three supervised urine samples 
per week (Petersson, 2013). Treatment 
must be discontinued if the patient cannot 
promote the achievement of the goals. In 
addition, treatment may be discontinued 
if the patient skips treatment for more than 
a week, repeatedly takes drugs, uses alco-
hol in excess, manipulates urine samples, 
is convicted for a drug offence or an ag-
gravated drug offence or repeatedly com-
mits a minor drug offence during treat-
ment (Läkemedelsassisterad behandling, 
2009). The costs of substitution treatment 
in Sweden have been estimated at EUR 
10,700 (SEK 100,000) per patient per year 
(Erikson, 2014).
In Denmark and Iceland, there is no data 
available on the dosages of substitution 
treatment medication. In Finland, the av-
erage daily dose of methadone is 102 mg 
and the average daily dose of buprenor-
phine products is 16 mg (EMCDDA, 2011). 
The doses are similar in Norway (Waal et 
al., 2013). In Sweden, too, most patients 
receive similar doses as Finnish patients: 
83% of methadone patients receive 60–
120 mg per day, and 87% of patients tak-
ing buprenorphine products receive 8–24 
mg per day (Socialstyrelsen, 2012).
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Table 5. Numbers of deaths during substitution treatment in the Nordic countries.
Variable Finland1 Sweden2 Norway3 Denmark4 Iceland5
Number of patients 1,362 3,705 7,038 7,600 90–100
Deaths/year 19 (1.4%) 99 (2.7%) 84 (1.2%) 27 (0.3%) n.a.
1 Subnational data from 2013. The data of 2013 are based on a specific e-mail survey directed at the six largest local 
authorities. The number of patients covers only part of the patients treated by the local authorities that responded to 
the survey. Data were received from municipalities of Espoo, Helsinki, Tampere, Turku, and Vantaa. The figure includes 
all patients treated during the year. 
2 Data for Sweden from 2012 (Socialstyrelsen, 2012). The number of substitution treatment patients in the table is 
lower than the total number of patients in Table 1, which includes both the prescription register data and the number 
of patients obtained as a result of a telephone survey directed at treatment units. Known cases of death are based on 
substitution treatment patient data found in the prescription register. 
3 Data for Norway from 2012 (Waal et al., 2013).
4 The number of patients in Denmark is based on data for 2011 (Narkotikasituation…2014) and the number of deaths 
is based on data for 2012 (K. Frederiksen, personal communication, 21 February, 2014). 
5 Data from 2013 (V. Rúnarsdóttir, personal communication, 7 March, 2014).
Deaths and discontinuations 
during treatment
There are many similarities and some in-
teresting differences between the Nordic 
countries in the goals and functioning of 
the treatment systems. Sweden has the 
most straightforward system: the treat-
ment aims for total abstinence and patients 
who are unable of this cannot continue 
their treatment. The flip side of this is that 
the treatment of relatively many patients 
is involuntarily discontinued (in 2011, the 
treatment of 350 patients was discontin-
ued and almost always involuntarily due 
to substance abuse). In addition, the mor-
tality rate of Swedish substitution treat-
ment patients is high: in 2011, a total of 99 
patients died (Table 5). The high mortality 
rates of 2011 do not seem to be a statistical 
anomaly: there were 77 deaths in 2010 and 
96 deaths in 2009 (Socialstyrelsen, 2012). 
According to the EMCDDA’s definition, 
the total number of drug-related deaths 
include deaths resulting from accidental 
or intentional poisoning and mental dis-
orders due to drug use (Varjonen, Tanhua, 
& Forsell, 2014). In Sweden, there were a 
total of 239 deaths due to these reasons in 
2011 and 269 in 2010 (EMCDDA, 2012a). 
The number of poisonings due to metha-
done has strongly increased in Sweden in 
recent years, but there are no clear signs of 
any connection between the increase and 
substitution treatment (Fugelstad, Johans-
son, & Thiblin, 2010).
The Danish system represents the most 
flexible way of implementing substitution 
treatment: patients do not have to wait 
long and the treatment is adapted to the 
patient’s situation. Mortality in propor-
tion to the number of patients is remark-
ably low (0.3%), but this reflects more the 
low-threshold nature of the Danish system 
than the actual level of mortality among 
substitution treatment patients. There 
were a total of 190 drug-related deaths in 
Denmark in 2011 and 222 deaths in 2010 
(Sundhedsstyrelsen, 2013b). Denmark’s 
discontinuation rate is similar to the other 
Nordic countries, but it should be noted 
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that in Denmark, discontinuation of treat-
ment is mainly voluntary (K. Frederiksen, 
personal communication, 21 February, 
2014). 
In Norway, the system has become more 
flexible as a result of the decree that en-
tered into effect in 2010. Treatment aiming 
for harm reduction has been established 
in addition to rehabilitative treatment. 
In Norway, where the overdose-induced 
mortality rate of heroin users has been 
very high even in international compari-
son (Simonsen et al., 2011), there were 84 
deaths of substitution treatment patients 
in 2012, with 54 cases the year before 
(Waal et al., 2013). The total number of 
drug-related deaths in Norway was 248 in 
2010 and 285 in 2009 (EMCDDA, 2012b). 
The number of treatments discontinued 
involuntary has considerably decreased 
in Norway in recent years, from 250 cases 
in 2007 to 65 cases in the whole country 
in 2012 (Waal et al., 2013). Adherence to 
treatment was also high in 2012: of pa-
tients who were in treatment at the begin-
ning of the year or started treatment during 
the year, 92% were still in treatment at the 
end of the year, and 95% of patients had 
never discontinued their treatment (Waal 
et al., 2013). The percentage of involun-
tary discontinuations of treatment by the 
treatment unit was low in Norway com-
pared with Sweden, for example: 65 cases 
in 2012 (16% of discontinued treatments) 
and 39 cases in 2011 (8% of discontinued 
treatments) (Waal et al., 2013). 
There is no comprehensive data avail-
able on the deaths during treatment or 
the discontinuations of treatment from 
Finland. According to data collected from 
Espoo, Helsinki, Tampere, Turku and Van-
taa3 (Table 5), 19 substitution treatment pa-
tients (N=1,362) died in 2013 during treat-
ment. There are probably many reasons for 
this relatively low number of deaths. It is 
probable that the Finnish opioid culture 
with buprenorphine as the main substance 
protects Finnish users to some extent, be-
cause the risk of dying from an overdose 
of buprenorphine is considerably lower 
compared with opiates (Uosukainen et al., 
2013). In 2011, there were a total of 197 
drug-related deaths in Finland, of which 
165 were poisonings. In 2010, there were 
156 drug-related deaths, of which 132 
were poisonings (Varjonen et al., 2014). 
In Helsinki, Tampere, Vantaa and Espoo, a 
total of 97 patients discontinued treatment 
in 2013 (N= 1,221). The number of dis-
continued treatments proportioned to the 
total number of patients varied greatly be-
tween the cities. This probably indicates 
differences in treatment practices between 
local authorities or treatment units. 
Discussion
The situations in Finland, Norway, Den-
mark, Iceland and Sweden are different 
with regard to the expansion of and need 
for substitution treatment and the use of 
opioids. For example, substitution treat-
ment is no longer increasing in Denmark, 
while it has expanded rapidly in recent 
years in Norway and also Sweden, even if 
the latter still restricts the access to treat-
ment (such as treating only those opiate 
users who are over 20 years of age). In Fin-
land, the coverage of treatment is propably 
lower than in Sweden and Norway. 
The availability of treatment is an im-
portant quality criterion and indirect ef-
fectiveness criterion. At the beginning of 
the 2000s, poor accessibility of substitu-
tion treatment was a problem in Finland. 
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Treatment is maybe more extensively 
available, but current waiting times have 
not been surveyed. 
The Finnish treatment system is more 
decentralised than the Swedish and Nor-
wegian systems; that is, Finland has many 
small treatment units. This may indicate 
great differences in treatment practices, as 
treatment provided in Finland is also lack-
ing central steering and nationwide guide-
lines on the content of treatment. Finnish 
medication policies vary between local au-
thorities and treatment units. It would be 
important to consider their suitability in 
relation to the use of opioids purchased in 
the street and the objectives of treatment 
(harm reduction vs. rehabilitation). In-
creased use of methadone for substitution 
treatment, according to the WHO’s recom-
mendation, could be suitable for Finland 
(World Health Organization, 2014). 
There is very little systematic data avail-
able on the backgrounds and circumstanc-
es of patients in treatment, even though 
such data would be important for the de-
velopment of treatment. For example, a 
homeless substitution treatment patient 
is basically much worse off than a patient 
with a permanent home. Lack of hous-
ing or poor social resources also requires 
smooth co-operation between different au-
thorities.
In our comparison, Sweden showed high 
mortality rates during substitution treat-
ment. A number of contributing factors 
to this can be found: Compared with Fin-
land, the patient group is different (mainly 
heroin users) and the number of drug-re-
lated deaths in general has been increasing 
for a long time. One reason may be the fact 
that substitution treatment is not allowed 
in involuntary treatment units. 
When developing the treatment system 
of opioid addicts in Finland, particular at-
tention should be paid to shortening the 
waiting times for treatment, improving 
adherence to treatment and co-operation 
with the education and employment au-
thorities. With regard to follow-up, it is 
important to develop national-level sys-
tematic register data on treatment, to en-
able comparable data on waiting times, 
medications and methods used, termina-
tion of treatment and treatment-related 
mortality rates. Due to the scattered nature 
and short history of the Finnish system, it 
is important to draft national guidelines 
for Finland.
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